{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:56:28Z","timestamp":1760648188837,"version":"build-2065373602"},"reference-count":3,"publisher":"Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.","issue":"3","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Alerg Mex"],"abstract":"<jats:p>Reporte de caso: Mujer de 24 a\u00f1os, con asma(2013) y rinitis al\u00e9rgica(2014), tratada con inmunoterapia subcut\u00e1nea durante 3 a\u00f1os, salmeterol\/fluticasona inhalado y antihistam\u00ednicos por unidad externa. Acude a nuestro servicio (2019), a su ingreso persiste con descontrol de asma, uso diario de inhalador de rescate y rinitis moderada-grave persistente. Se ajusta tratamiento de asma de acuerdo a gu\u00edas alcanzando paso 4 de tratamiento, persistiendo descontrol (ACT 16 puntos), cumpliendo criterios para inicio de Benralizumab 30 mg (26\/7\/2024), completando dos aplicaciones con mejor\u00eda cl\u00ednica(ACT), sin embargo, durante dos dosis curs\u00f3 con fiebre, cefalea, mialgias y artralgias por lo que se suspende tratamiento, con empeoramiento de los s\u00edntomas, se decide cambio de biotecnologico a mepolizumab(04\/02\/25), con efectos adeversos a tercera dosis.\nConclusi\u00f3n: Un porcentaje de pacientes con asma cursara con cuadro grave, el 80% con fenotipo eosinof\u00edlico, asociado a dif\u00edcil control y aumento de exacerbaciones. En estos pacientes los anticuerpos monoclonales est\u00e1n indicados. Benralizumab dirigido a IL-5R\u03b1, induce depleci\u00f3n de eosin\u00f3filos a trav\u00e9s de citotoxicidad mediada por anticuerpos. Se han realizado diversos estudios(MELTEMI) para evaluar la seguridad de su uso a largo plazo, dentro de los efectos adversos no graves m\u00e1s comunes se encuentran infecci\u00f3n viral de v\u00edas respiratorias superiores(47.3), mientras los efectos adversos menos frecuentes son cefalea y las artralgias representan un 20.9% y 6.4%. Biotecnol\u00f3gicos reducen exacerbaciones, reduce el uso de corticosteroides, mejora el control y calidad de vida, sin embargo no est\u00e1n exentos de generar efectos adversos, inclusive los menos frecuentes se deben identificar para valorar continuar tratamiento.\nPalabras clave: Asma; Benralizumab; Mepolizumab.<\/jats:p>","DOI":"10.29262\/ram.v72i3.1518","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T14:24:00Z","timestamp":1759242240000},"page":"232","source":"Crossref","is-referenced-by-count":1,"title":["&lt;b&gt;Reacciones adversas a biotecnol\u00f3gicos dirigidos a IL-5 &lt;\/b&gt;","&lt;b&gt;Adverse reactions to biotechnological agents targeting IL-5\u00a0&lt;\/b&gt;"],"prefix":"10.29262","volume":"72","author":[{"given":"Guillermo","family":"P\u00e9rez Dimas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Velazquez Samano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Velasco Medina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Albarr\u00e1n God\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itzel Yoselin","family":"Sanchez P\u00e9reZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Citlalli","family":"Ramirez Casillas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11808","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"#cr-split#-62729.1","doi-asserted-by":"crossref","unstructured":"Iniciativa Global para el Asma. (2024). Estrategia global para el manejo y la prevenci\u00f3n del asma. Recuperado de https:\/\/ginasthma.org\/2024-report\/ \u2022 Moore, W. C., Kornmann, O., Humbert, M., Poirier, C., Bel, E. H., Kaneko, N., Smith, S. G., Martin, N., Gilson, M. J., Price, R. G., Bradford, E. S., & Liu, M. C. (2022). Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). The European respiratory journal, 59(1), 2100396. \u2022 Drick N, Milger K, Seeliger B, Fuge J, Korn S, Buhl R, Schuhmann M, Herth F, Kendziora B, Behr J, Kneidinger N, Bergmann KC, Taube C, Welte T, Suhling H. Switch from IL-5 to IL-5-Receptor \u03b1 Antibody Treatment in Severe Eosinophilic Asthma. J Asthma Allergy. 2020 Nov 11;13:605-614. doi: 10.2147\/JAA.S270298. PMID: 33204117","DOI":"10.2147\/JAA.S270298"},{"key":"#cr-split#-62729.2","doi-asserted-by":"crossref","unstructured":"PMCID: PMC7667509. \u2022 Dragonieri S, Portacci A, Quaranta VN, Carpagnano GE. Advancing Care in Severe Asthma: The Art of Switching Biologics. Adv Respir Med. 2024 Feb 21;92(2):110-122. doi: 10.3390\/arm92020014. PMID: 38525773","DOI":"10.3390\/arm92020014"},{"key":"#cr-split#-62729.3","doi-asserted-by":"crossref","unstructured":"PMCID: PMC10961683. \u2022 Bourdin, A., Chupp, G., Jackson, D. J., Cohen, D., Emerath, U., Shavit, A., Kurdyukova, Y., & Menzies-Gow, A. (2024). MELTEMI and COLUMBA: 5-Year Comparative Safety Analysis of Benralizumab and Mepolizumab. The journal of allergy and clinical immunology. In practice, 12(8), 2074-2083.e4. https:\/\/doi.org\/10.1016\/j.jaip.2024.04.033","DOI":"10.1016\/j.jaip.2024.04.033"}],"container-title":["Revista Alergia M\u00e9xico"],"original-title":[],"link":[{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1518\/2768","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1518\/2768","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T14:24:04Z","timestamp":1759242244000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/view\/1518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":3,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9,30]]}},"URL":"https:\/\/doi.org\/10.29262\/ram.v72i3.1518","relation":{},"ISSN":["2448-9190","0002-5151"],"issn-type":[{"type":"electronic","value":"2448-9190"},{"type":"print","value":"0002-5151"}],"subject":[],"published":{"date-parts":[[2025,9,30]]}}}